Implementation of a dose calculator for vancomycin to achieve target trough levels of 15-20 μg/mL in persons undergoing hemodialysis

Clinical Infectious Diseases

Volumn 53, Issue 2, 2011, Pages 124-129

  Vandecasteele, Stefaan J ^a   De Bacquer, Dirk ^b   De Vriese, An Sabine ^a  

^a AZ Sint Jan Brugge Oostende AV ^*  (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ACCURACY; AGED; ARTICLE; BODY WEIGHT; DOSE CALCULATION; FEMALE; HEMODIALYSIS; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BODY WEIGHT; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PLASMA; RENAL DIALYSIS; TIME FACTORS; VANCOMYCIN;

EID: 79959736462     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir337     Document Type: Article

References (23)

1. Vandecasteele SJ, Boelaert JR, De Vriese AS. Staphylococcus aureus infections in hemodialysis: what a nephrologist should know. Clin J Am Soc Nephrol 2009; 4:1388-400.
2. Bloembergen WE, Port FK. Epidemiological perspective on infections in chronic dialysis patients. Adv Ren Replace Ther 1996; 3:201-7. (Pubitemid 26240924)
3. Lafrance JP, Rahme E, Lelorier J, Iqbal S. Vascular access-related infections: definitions, incidence rates, and risk factors. Am J Kidney Dis 2008; 52:982-93.
4. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984; 25:433-7. (Pubitemid 14129598)
5. Pallotta KE, Manley HJ. Vancomycin use in patients requiring hemodialysis: a literature review. Semin Dial 2008; 21:63-70.
6. Pea F, Furlanut M, Negri C, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother 2009; 53:1863-7.
7. Vandecasteele SJ, De Vriese AS. Recent changes in vancomycin use in renal failure. Kidney Int 2010; 77:760-4.
8. Lindholm DD, Murray JS. Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis. N Engl J Med 1966; 274:1047-51.
9. Vandecasteele SJ, De Vriese AS. Review: vancomycin dosing in patients on intermittent haemodialysis. Semin Dial 2011; 24:50-5.
10. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66:82-98.
11. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44:1208-15. (Pubitemid 46651246)
12. Garnier F, Chainier D, Walsh T, et al. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J Antimicrob Chemother 2006; 57:146-9. (Pubitemid 43057073)
13. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
14. Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother 2009; 53:483-6.
15. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43:925-42. (Pubitemid 39447034)
16. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42(Suppl 1):S35-9. (Pubitemid 41832063)
17. Meyer CC, Calis KA. New hemodialysis membranes and vancomycin clearance. Am J Health Syst Pharm 1995; 52:2794-6.
18. Barth RH, DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int 1996; 50:929-36. (Pubitemid 26302682)
19. DeSoi CA, Sahm DF, Umans JG. Vancomycin elimination during highfluxhemodialysis: kinetic model and comparison of four membranes. Am J Kidney Dis 1992; 20:354-60.
20. Foote EF, Dreitlein WB, Steward CA, Kapoian T, Walker JA, Sherman RA. Pharmacokinetics of vancomycin when administered during high flux hemodialysis. Clin Nephrol 1998; 50:51-5. (Pubitemid 28349774)
21. Mason NA, Neudeck BL, Welage LS, Patel JA, Swartz RD. Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: post-dialysis versus intradialytic administration. Clin Nephrol 2003; 60:96-104. (Pubitemid 36975184)
22. Ariano RE, Fine A, Sitar DS, Rexrode S, Zelenitsky SA. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis. Am J Kidney Dis 2005; 46:681-7. (Pubitemid 41383946)
23. Pai AB, Pai MP. Vancomycin dosing in high flux hemodialysis: a limited-sampling algorithm. Am J Health Syst Pharm 2004; 61:1812-6. (Pubitemid 39481362)